188 Re-SSS Lipiodol Radioembolization in HCC Patients: Results of a Phase 1 Trial (Lip-Re-01 Study).

Etienne GarinXavier PalardYan RollandSamuel Le SourdNicolas LepareurValérie ArdissonChristelle BouvrySophie LaffontBoris Campillo-GimenezEric BellissantJulien Edeline

Published in: Cancers (2023)

Re-SSS lipiodol was confirmed, resulting in encouraging responses for a Phase 1 study. As the 3.6 GBq activity proved to be safe, it will be used in a future Phase 2 study.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
open label
prognostic factors
peritoneal dialysis
clinical trial
double blind
randomized controlled trial
placebo controlled
patient reported